Navigation Links
Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing
Date:5/26/2010

NORTHBROOK, Ill., May 26 /PRNewswire/ -- Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review.  Horizon is seeking FDA approval of DUEXA for the reduction of the risk of development of upper gastrointestinal ulcers in patients with arthritis and pain.  The PDUFA date for completion of the FDA's review for DUEXA is expected in the first quarter of 2011.

"As the pain and arthritis market continues to grow, safe and effective treatments are desperately needed for physicians and patients concerned about the gastrointestinal impact of NSAIDs," said Timothy P. Walbert, chairman, president and chief executive officer of Horizon Pharma.  "We look forward to working closely with the FDA to bring DUEXA to market as quickly as possible.  The filing of the DUEXA NDA brings us one step closer to providing the millions suffering from mild-to-moderate pain and arthritis with a new treatment option."

The DUEXA NDA submission was based on two Phase 3 clinical studies (REDUCE-1 and REDUCE-2), which demonstrated that patients with mild-to-moderate pain treated with DUEXA developed approximately fifty percent less upper gastrointestinal (GI) ulcers) compared to patients treated with ibuprofen alone.   The trials were conducted in the U.S. via a Special Protocol Assessment (SPA) with the FDA and enrolled more than 1,500 patients.  Based on these data, the Company also plans to submit a marketing authorization appl
'/>"/>

SOURCE Horizon Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
2. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
3. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
4. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
5. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
6. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
7. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
8. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
9. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
10. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
11. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... (EMA) of the Marketing Authorization Application (MAA) for ... granted the company,s request for accelerated assessment, which ... review time.   The MAA, and ...
(Date:12/24/2014)... -- In response to urgent requests from the Deputy Minister of ... , Direct Relief delivered two 10-bed medical tents to ... local health workers who contract Ebola while fighting the outbreak. ... was constructed for foreign health care workers who may contract ... Sierra Leonean health workers. With Sierra ...
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ( ... offices in Aliso Viejo , California.  ... to the tremendous growth and worldwide expansion, a new ... patented SnoreRx, the anti snore cure have exceeded our ... "We are now in 23 countries and will ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
... INDIANAPOLIS, Jan. 18, 2011 Eli Lilly and Company (NYSE: ... the fourth quarter and full year of 2010 on Thursday, ... on that day with the investment community and media to ... conference call will be held from 9:00 a.m. to 10:00 ...
... Jan. 18, 2011 DW Healthcare Partners (DWHP), a ... announced the appointment of Bradley Lanham as the new ... DWHP has now completed acquisitions of institutional pharmacies specializing ... including Texas, Nevada, Utah, Idaho and Colorado. ...
Cached Medicine Technology:DW Healthcare Partners Announces New CEO on Heels of Increased Investment in Institutional Pharmacy Sector 2
(Date:12/25/2014)... December 25, 2014 The short film “Color ... created in honor of a true 9/11 hero, Welles Remy ... festivals including the 24 hours of Nuremberg International Short Film ... , Actress, screenwriter and director Luciana Lagana ... film together with her husband, Gregory Graham - ...
(Date:12/25/2014)... December 25, 2014 Recently, LunaDress.co.uk has updated its ... and related accessories. Now, all of the models at LunaDress.co.uk come ... a groom lifts the wedding veil can turn out to be ... charm. A wedding veil can always bring surprise to a wedding. ... on how to choose veils for a big day . ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
(Date:12/25/2014)... Residents at Abernethy Laurels ... their generous spirit by providing holiday gifts to ... Network- Grandparents Raising Grandchildren program. , Following a ... largest Christmas tree on the campus of the ... of the Abernethy Village Association (AVA). Each holiday ...
(Date:12/24/2014)... Epigenetics finds applications in a large number of ... developmental biology, and research for metabolic and genetic disorders. ... widely used techniques for the discovery and development of ... is rapidly growing worldwide. In 2012, there were 14.1 ... 32.6 million people living with cancer (within five years ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3
... are more common in women than in men, says Coping ... School. Scientists are// examining hormonal and biological factors, as well ... ,Women are twice as likely to suffer from ... are three times as likely to have agoraphobia (fear of ...
... by retina surgeons at The Methodist Hospital shows unprecedented ... treated with Lucentis? for wet// age-related macular degeneration (AMD), ... Journal of Medicine. AMD is a major cause of ... causes of blindness in people over 60. ...
... toll from the mosquito-borne virus has risen to six in ... died of the disease in the paediatric ward of King ... the Farrukhabad district hospital,' V.S. Nigam, health department spokesman told ... cases has shot up to 199 in the state with ...
... that behavioral therapies can benefit children who have problems falling ... ,The American Academy of Sleep Medicine (AASM) appointed a team ... and toddlers. ,According to study author Jodi A. ... shown 20 to 30 percent of young children have sleep ...
... Pradesh villager suffering from a serious kidney ailment died ... premier hospital here//, apparently because he could not afford ... of a window of the nephrology ward of the ... he was being treated, hospital sources told IANS. ...
... debate on the issue of organ donation. The author advocates ... will help in meeting the excessive demand for transplants and ... is an organ transplant surgeon by profession has opined that ... requirement for organs whilst remaining on the right side of ...
Cached Medicine News:Health News:Results for Wet Age-Related Macular Degeneration Show Significant Vision Improvements 2
Diamond Point Bone Probe with Ortho-Grip® silicone rubber palm style handles and,stainless steel impactor caps....
Steroid-eluting, single-pass lead. CapSure VDD2 optimizes VDD therapy and offers easier handling, proven performance, and choice....
CapSureSP Novus 5594 is a J-shaped, endocardial, tined pacing lead. provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but wi...
Steroid eluting pacemaker leads...
Medicine Products: